Skip to main content
. 2023 Jun 20;18(2):156–164. doi: 10.30699/ijp.2023.563014.2986

Table 3.

Correlation between MMP-9 and CCR7 expression with clinicopathological features of LSCC

Variables N (%) MMP-9 P CCR7 P
High (n=33) Low (n=27) High (n=36) Low (n=24)
Gender
Male 56 (93.3%) 30 (90.9%) 26 (96.3%) 0.405 33 (91.7%) 23 (95.8%) 0.526
Female 4 (6.7%) 3 (9.1%) 1 (3.7%) 3 (8.3%) 1 (4.2%)
Age
< 50 years 11 (18.3%) 6 (18.2%) 5 (18.5%) 0.360 8 (22.2%) 3 (12.5%) 0.159
50-59 years 17 (28.3%) 7 (21.2%) 10 (37%) 7 (19.4%) 10 (41.7%)
> 60 Years 32 (53.3%) 20 (60.6%) 12 (44.4%) 21 (58.3%) 11 (45.8%)
Tumor Size
< 4 cm 36 (60%) 14 (42.4%) 22 (81.5%) 0.002* 15 (41.7%) 21 (87.5%) <0.001*
> 4 cm 24 (40%) 19 (57.6%) 5 (18.5%) 21 (58.3%) 3 (12.5%)
Tumor differentiation
Well 13 (21.7%) 4 (12.1%) 9 (33.3%) 0.047 6 (16.7%) 7 (29.2%) 0.250
Moderate-Poor 47 (78.3%) 29 (87.9%) 18 (66.7%)
Lymphovascular invasion
Yes 6 (10%) 3 (9.1%) 3 (11.1%) 0.795 4 (11.1%) 2 (8.3%) 0.725
No 54 (90%) 30 (90.9%) 24 (88.9%) 32 (88.9%) 22 (91.7%)
pT Stage
1-2 5 (8.3%) 2 (6.1%) 3 (11.1%) 0.481 2 (5.6%) 3 (12.5%) 0.340
3-4 55 (91.7%) 31 (93.9%) 24 (88.9%) 34 (94.4%) 24 (87.5%)

* Significant value (P< 0.05)